1. Background {#sec1}
=============

Diabetes is one of the four main noncommunicable diseases (NCDs) identified by the World Health Organization (WHO), besides the cardiovascular disease, cancer, and chronic respiratory diseases \[[@B1]\]. Asia has become the major site of a quickly emerging diabetes epidemic. In Malaysia, the latest National Health and Morbidity Survey in 2008 already demonstrated an increase of prevalence of diabetes mellitus from 8.3% to 11.6% \[[@B2]\]. Type 2 diabetes mellitus (T2DM) is a complex polygenic disorder characterized by impaired insulin resistance, insulin secretion, and dysregulation of lipid and protein metabolism with environmental and genetic factors \[[@B3]\]. The complications of diabetes have become the leading causes of mortality and morbidity worldwide \[[@B4]\]. The prevalence of T2DM is swiftly increasing to 300 million people by the year 2025 \[[@B5]\]. Although several association studies suggested various candidate genes for T2DM in different populations, the role of genetic polymorphisms involved in the development of diabetes still remains unclear \[[@B6]\]. The ATP-binding cassette transporter A1 (ABCA1) gene located on the chromosome 9 region q31.1 involved in the transport of cholesterol and phospholipids from cells to lipid-poor apolipoproteins \[[@B7]\]. Besides, some investigations demonstrated that familial hypoalphalipoproteinemia can be caused by heterozygosity and Tangier disease can be caused by homozygous mutations. Moreover, genetic and molecular biology researchers have suggested that low plasma HDL-cholesterol can reflect an impaired ABCA1 pathway that can also elevate the accumulation of cholesterol in tissue macrophages \[[@B10]\].

Analyzing the genetic and allelic frequency of polymorphisms among case and control studies can provide supporting evidence to show their role in individual subjects. The genetic polymorphisms of ABCA1 gene provide a basis for studying the association between genetic variants and the development of T2DM in this ethnic group. Based on literature review, most of the studies were done on 3 common polymorphisms, so this study was conducted to determine genetic polymorphism of the rs2230806 (R219K), C69T (rs1800977), and R230C (rs9282541) among T2DM subjects.

2. Results {#sec2}
==========

A total of 329 subjects were approached in this study that were divided into 2 groups: 165 controls and 164 T2DM subjects. In this study, the association of anthropometric and social demographic factors and major risk factors in T2DM with ABCA1 polymorphism among Malaysian subjects was investigated.

The means of age, BMI, systolic blood pressure (SBP), FPG, HbA1c, HDL, and triglyceride (TG) among T2DM patients were higher than control group; moreover, diastolic blood pressure (DBP), low density lipoprotein (LDL), and cholesterol in control subjects were higher than T2DM patients. The control samples had mean age 54.97 ± 11.79 and patients had mean age 62.14 ± 9.56. Mean BMI were almost equal: 27.08 ± 6.26 in control and 28.60 ± 13.98 in case samples. Mean of SBP among controls was 137.89 ± 20.22 and among case subjects was 141.83 ± 24.41 and mean of DBP was 79.54 ± 10.52 between control groups and 78.32 ± 12.14 between case subjects. Mean of FPG was higher among case subjects (8.66 ± 3.50) and in control samples was 5.45 ± 1.31. Mean of HbA1c among patients (7.90 ± 2.08) is higher than controls (5.94 ± 0.65). The means of cholesterol, LDL, HDL, and TG between case and control subjects are almost equal. Maximum age between case and control subjects is 85 years and minimum age in control is 26 years and in case is 41 years. Based on this table the significant difference was detected in the level of age (*P* value = 0.000), FPG (*P* value = 0.000), HbA1c (*P* value = 0.000), LDL (*P* value = 0.010), and TG (*P* value = 0.000) between T2DM and control subjects ([Table 1](#tab1){ref-type="table"}).

2.1. R219K {#sec2.1}
----------

Analysis of R219K polymorphism with 73 bp PCR product with mutation (G→A) was amplified by PCR-HRM. [Figure 1](#fig1){ref-type="fig"} showed three different graphs that can detect three different genotypes of R219K polymorphism. The genotypic and allelic frequencies of R219K were shown in [Table 2](#tab2){ref-type="table"} that demonstrated the significant difference genotypes of this polymorphism. The clinical and biochemical characteristics were demonstrated in [Table 3](#tab3){ref-type="table"} for this polymorphism. Based on this table the *P* value showed FPG (0.036) was significantly higher in WT in both groups. There was significantly higher difference in the mean of HbA1c of WT for both subjects (*P* = 0.001).

2.2. C69T {#sec2.2}
---------

Analysis of C69T polymorphism with 85 bp PCR product length with mutation (C→T) was amplified by PCR-HRM. [Figure 2](#fig2){ref-type="fig"} showed three different graphs that can detect three different genotypes of C69T polymorphism. The genotypic and allelic frequencies of C69T were shown in [Table 2](#tab2){ref-type="table"} that did not demonstrate any differences for this polymorphism. The clinical and biochemical characteristics of this polymorphism were demonstrated in [Table 4](#tab4){ref-type="table"}.

2.3. R230C {#sec2.3}
----------

Analysis of R230C polymorphism with 87 bp PCR product length with mutation (C→T) was amplified by PCR-HRM. [Figure 3](#fig3){ref-type="fig"} showed three different graphs that can detect three different genotypes of R230C polymorphism. The genotypic and allelic frequencies of R230C were shown in [Table 2](#tab2){ref-type="table"} that did not demonstrate any differences for this polymorphism. The clinical and biochemical characteristics of this polymorphism were demonstrated in [Table 5](#tab5){ref-type="table"}.

3. Discussion {#sec3}
=============

As revealed in some investigations, the worldwide prevalence of diabetes has gone up and this represents the importance of the study on diabetes; moreover, in Malaysia, the latest National Health and Morbidity Survey in 2008 has already demonstrated an increase in the prevalence of diabetes mellitus from 8.3% to 11.6% \[[@B8]\]. The proportion of Malays was higher in both T2DM and control subjects in this study (50.6% and 50.3%, resp.) in comparison with Indians and Chinese (29.9% and 30.3%, resp., for Indians and 19.5% and 19.4%, resp., for Chinese). Moreover, the proportion of males was higher in T2DM and control subjects (62.8% and 52.7%, resp.) in comparison with females (37.2% and 47.3%, resp.). The significant difference in the levels of age (*P* = 0.000), FPG (*P* = 0.000), LDL (*P* = 0.010), and TG (*P* = 0.000) was observed among the subjects. In previous reports a significant difference was detected in the levels of BMI, HDL, LDL, TG, cholesterol, FPG, SBP, and DBP between T2DM and healthy subjects \[[@B10], [@B9]\]. Among overweight/obese population demographic and clinical characteristics were evaluated which demonstrated no significant differences in the level of HDL and LDL but statistical differences were detected in the levels of BMI, cholesterol, and TG \[[@B11]\]. In the current study, there were no significant differences between genotypes and subjects for R230C and C69T polymorphisms. But, regarding R219K there was a significant difference between subjects. Allele frequencies of these polymorphisms revealed no significant difference of R230C but there was a significant difference between alleles of R219K and C69T. Based on genotype and allele frequency of polymorphisms according to gender among subjects, there was no significant difference between genotypes and gender among subjects for any of the polymorphisms but A allele of R219K and C allele of C69T and T allele of R230C had significant differences between genders among subjects.

Genotype and allele frequencies of each polymorphism revealed no significant difference for genotype and allele of C69T and R230C according to race among subjects but R219K had a significant difference in HOM and A allele. R219K was significantly different between metabolic syndrome patients and healthy subjects based on Değer\'s group research \[[@B12]\].

Opposite to those studies, some researchers showed the significant differences between T2DM and controls: they found TT genotype was significantly higher in controls than in patients, but Alharbi and his colleagues showed the frequency of T allele was higher among patients and Ergen et al. found that T allele was higher in control groups; moreover these 2 groups did not find any association between C69T and lipid profiles \[[@B10], [@B9]\]. R230C polymorphism of ABCA1 gene associated with lower HDL; moreover, C230 allele had a significant association with lower cholesterol and HDL level as well. However, no association was detected between C230 allele and T2DM \[[@B13]\].

Among overweight/obese and control populations there was no significant difference for genotype frequency \[[@B11]\]. [Table 6](#tab6){ref-type="table"} demonstrated the conflicting results of genetic variants of ABCA1 gene found in different populations compared with the current study.

4. Conclusion {#sec4}
=============

The present study has showed a genetic association for R219K, C69T, and R230C polymorphisms of ABCA1 gene among Malaysian T2DM patients compared to control subjects. Replication studies with a larger number of samples on a homogenous study population are strongly recommended to confirm the association of ABCA1 gene polymorphisms with T2DM.

In the current study, some limitations have been considered. The present study provided only genetic association of ABCA1 gene polymorphisms with T2DM among Malaysian subjects. Apart from the ABCA1 gene polymorphisms, other polymorphisms such as A2589G, G3456C, R1851X, and K776N need to be analyzed to determine the association of the other candidate gene polymorphisms with T2DM and other defects. [Table 6](#tab6){ref-type="table"} shows the conflicting results of genetic variants found in different populations.

5. Methods {#sec5}
==========

5.1. Study Subjects {#sec5.1}
-------------------

Ethical approval has been obtained from the Ethical Committee of the National Heart Institute, Malaysia (Reference number IJNEC/05/10 (02)). A total of 164 T2DM subjects were collected from the National Heart Institute, Kuala Lumpur. Subjects were selected as adults \> 30 years of age who were already diagnosed with T2DM and participated in IJN for their T2DM treatment. A questionnaire in both Malay and English languages was obtained to assess the sociodemographic factors. Informed consent was obtained from all the subjects who have participated in this study. A total of 165 control individuals were recruited from the healthy respondents who did not have T2DM at the time of sample collection. The subjects who had been diagnosed with cancer, type 1 diabetes, genetic malformation, and pregnancy are excluded from this study.

5.2. Genomic DNA Extraction {#sec5.2}
---------------------------

The buccal and blood samples were collected from the respective subjects. The genomic DNA was extracted from blood and buccal samples by using the extraction kits (QIGEN) and used for amplification of the candidate genes and then the extracted genomic DNA was stored at −20°C for further analysis. PCR optimization was done first for all primers, followed by DNA qualifications. The concentration of the extracted DNA was estimated using the NanoDrop in two OD wavelengths 260 nm and 280 nm.

5.3. Genotyping of ABCA1 Gene Polymorphisms {#sec5.3}
-------------------------------------------

Genotyping of these polymorphisms was done based on real time PCR-HRM and the primers were designed and synthesized by NextGene. The PCR product of samples that were amplified from the respective genes was sequenced and confirmed the product. Those samples were used as a positive control for the respective genes. The negative control consisted of PCR-grade water lacking the DNA template. All samples were genotyped by high resolution melting analysis by Rotor Gene 6000. PCR primers for R219K were forward primer CCATGTTGGAACGAAGTA and reverse primer GAAGTTTCTGAGCTTTGTG, for C69T were forward primer TCTCGCTCGCAATTACGG and reverse primer TGACCGATAGTAACCTCTGC, and for R230C were forward primer GATTGGCTTCAGGATGTCCATGTTG and reverse primer GTTTCTGAGCTTTGTGGCCT ACC. PCR was performed in a volume of 25 *μ*L consisting of about 1 *μ*L of genomic DNA, 0.5 *μ*L of each of the forward and reverse primers, 13 *μ*L of water, and 10 *μ*L Master Mix for HRM (EpiTect HRM Master Mix, QIGEN). The temperature was kept at 95 for 5 min for denaturation followed by 40 cycles of 20 s at 95°C, 10 s at 55°C, and 20 s at 72°C. The melting curves were normalized (temperature ranges on each side of the melting transition were chosen and the data points for a given sample were scaled between 0 and 100% fluorescent intensity). Used control samples (wild type (WT) and homozygous mutant (HOM)) were confirmed by sequencing. [Table 1](#tab1){ref-type="table"} demonstrated the sequence and length and Tm of each primer.

5.4. Statistical Analysis {#sec5.4}
-------------------------

The Statistical Package for Social Science (SPSS) (Version 21) was used to analyze the data in this study. Descriptive statistics were utilized to analyze all variable information such as demographics, anthropometric factors, and the genotypes of all the study subjects; moreover, all of these factors were compared by using Student\'s *t*-test; one-way ANOVA test was utilized to compare the group means and a level of *P* \< 0.05 was considered as statistically significant. Confidence intervals (95%) were reported where appropriate. Allelic frequencies were calculated by the gene counting method and the genotype distribution was calculated with Hardy-Weinberg expectations by a chi-squared test.
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![The difference graph of HRM analysis for the genotypes of R219K polymorphism. (a) demonstrated the normalized graph, (b) revealed the difference graph, and (c) was melting graph. In these graphs WT had higher Tm and HOM had lower Tm.](JDR2015-289846.001){#fig1}

![The difference graph of HRM analysis for the genotypes of C69T polymorphism. (a) demonstrated the normalized graph, (b) revealed the difference graph, and (c) was melting graph. In these graphs WT had higher Tm and HOM had lower Tm.](JDR2015-289846.002){#fig2}

![The difference graph of HRM analysis for the genotypes of R230C polymorphism. (a) demonstrated the normalized graph, (b) revealed the difference graph, and (c) was melting graph. In these graphs WT had higher Tm and HOM had lower Tm.](JDR2015-289846.003){#fig3}

###### 

Clinical and biochemical characteristics between T2DM and control subjects.

  Parameters             T2DM (*n* = 164)   Controls (*n* = 165)   *P* value
  ---------------------- ------------------ ---------------------- -----------
  Age (years)            62.14 ± 9.56       54.97 ± 11.79          0.000^\*^
  BMI (Kg/m²)            27.86 ± 5.14       27.08 ± 6.26           0.22
  WHR                    0.96 ± 0.15        0.95 ± 0.56            0.876
  SBP (mm Hg)            141.83 ± 24.41     137.89 ± 20.22         0.117
  DBP (mm Hg)            78.30 ± 12.14      79.55 ± 10.52          0.325
  FPG (mmol/L)           8.66 ± 3.50        5.45 ± 1.31            0.000^\*^
  HbA1c (mmol/mol)       7.98 ± 2.18        5.94 ± 0.65            0.000^\*^
  LDL (mmol/L)           2.35 ± 0.90        2.62 ± 0.95            0.010^\*^
  HDL (mmol/L)           1.26 ± 0.48        1.21 ± 0.43            0.303
  TG (mmol/L)            1.76 ± 1.20        1.27 ± 0.76            0.000^\*^
  Cholesterol (mmol/L)   4.38 ± 1.14        4.43 ± 1.17            0.675

Values shown are the mean ± SD, *P* \< 0.05.

^\*^Significant parameters.

###### 

Genotypic and allelic frequencies of R219K, C69T, and R230C, respectively, according to subjects.

                                         T2DM (%)      (95% CI)       Controls (%)   *P* value
  ----------------------- -------------- ------------- -------------- -------------- -----------
  R219K                   GG             94 (57.3%)                   56 (33.9%)      
  Genotypes and alleles   GA             55 (33.5%)                   77 (46.6%)     0.000^\*^
                          AA             15 (9.1%)                    32 (19.3%)      
  Alleles                 G              243 (74%)                    189 (57.2%)    0.000^\*^
                          A              85 (26%)                     141 (42.8%)    
                                                                                     
                          GG versus GA                 0.07--0.34                    0.001^\*^
  Post hoc test           GG versus AA                 0.11--0.49                    0.001^\*^
                          GA versus AA                 −0.09--0.29                   0.467
                                                                                     
  C69T                    CC             65 (39.6%)                   83 (50.3%)      
  Genotypes and alleles   CT             48 (29.2%)                   48 (29%)       NS
                          TT             51 (31%)                     34 (20.6%)      
                          C              154 (54.2%)                  190 (64.8%)    0.005^\*^
  Alleles                 T              150 (45.8%)                  116 (35.2%)    
                                                                                     
                          CC versus CT                 −0.18--0.06                   0.352
  Post hoc test           CC versus TT                 −0.29--−0.02                  0.018^\*^
                          CT versus TT                 −0.24--0.04                   0.179
                                                                                     
  R230C                   CC             69 (42%)                     64 (38.7%)      
  Genotypes and alleles   CT             72 (43.6%)                   67 (40.6%)     NS
                          TT             32 (19.3%)                   34 (20.6%)      
                          C              210 (63.9%)                  195 (59%)      0.695
  Alleles                 T              136 (36.1%)                  135 (41%)      
                                                                                     
                          CC versus CT                 0.11-0.12                     0.989
  Post hoc test           CC versus TT                 −0.04--0.27                   0.147
                          CT versus TT                 −0.04--0.26                   0.147

^\*^ *P* \< 0.05.

###### 

Clinical and biochemical characteristics among subjects according to genotypes of R219K.

                         T2DM (*n* = 164)   Controls (*n* = 165)   *P* value                                                           
  ---------------------- ------------------ ---------------------- ---------------- ---------------- ---------------- ---------------- -----------
  Age (years)            61.94 ± 9.20       61.40 ± 9.98           66.06 ± 9.76     54.94 ± 11.79    55.38 ± 12.11    54.06 ± 10.98    0.583
  BMI (Kg/m²)            27.68 ± 5.12       28.32 ± 5.54           27.29 ± 3.69     27.53 ± 8.86     27.17 ± 4.44     26.08 ± 4.24     0.767
  WHR                    0.95 ± 0.07        0.97 ± 0.25            0.96 ± 0.06      0.88 ± 0.13      1.02 ± 0.82      0.91 ± 0.06      0.791
  SBP (mm Hg)            145.45 ± 22.85     134.98 ± 25.86         145.85 ± 24.12   136.72 ± 20.59   138.12 ± 19.44   139.34 ± 21.93   0.479
  DBP (mm Hg)            78.21 ± 10.14      78.44 ± 15.15          78.28 ± 11.41    79 ± 11.21       79.36 ± 10.12    80.96 ± 10.43    0.481
  FPG (mmol/L)           8.76 ± 3.66        8.65 ± 3.39            8.11 ± 3.04      5.62 ± 1.14      5.35 ± 1.24      5.42 ± 1.69      0.036^\*^
  HbA1c (mmol/mol)       8.22 ± 2.14        7.76 ± 2.15            7.24 ± 2.46      5.92 ± 0.69      5.91 ± 0.63      6.07 ± 0.65      0.001^\*^
  LDL (mmol/L)           2.34 ± 0.92        2.33 ± 0.87            2.46 ± 0.94      2.71 ± 0.95      2.47 ± 0.91      2.80 ± 1.03      0.138
  HDL (mmol/L)           1.24 ± 0.40        1.27 ± 0.54            1.31 ± 0.69      1.28 ± 0.44      1.19 ± 0.46      1.10 ± 0.29      0.382
  TG (mmol/L)            1.85 ± 1.45        1.58 ± 0.76            1.90 ± 0.82      1.26 ± 0.79      1.29 ± 0.81      1.25 ± 0.58      0.139
  Cholesterol (mmol/L)   4.42 ± 1.19        4.29 ± 1.08            4.45 ± 1.11      4.66 ± 1.16      4.30 ± 1.21      4.34 ± 1.04      0.218

^\*^ *P* \< 0.05.

###### 

Clinical and biochemical characteristics among subjects according to genotypes of C69T.

                         T2DM (*n* = 164)   Controls (*n* = 165)   *P* value                                                           
  ---------------------- ------------------ ---------------------- ---------------- ---------------- ---------------- ---------------- -------
  Age (years)            61.93 ± 9.65       62.55 ± 10.10          62.04 ± 9.09     55.60 ± 11.50    54.51 ± 12.62    54.06 ± 11.55    0.958
  BMI (Kg/m²)            27.99 ± 5.07       27.98 ± 5.53           27.58 ± 4.94     26.98 ± 7.32     27.05 ± 5.22     27.35 ± 4.72     0.992
  WHR                    0.97 ± 0.23        0.95 ± 0.65            0.95 ± 0.07      1.00 ± 0.87      0.88 ± 0.05      0.91 ± 0.07      0.544
  SBP (mm Hg)            142.79 ± 20.84     143.76 ± 25.25         138.94 ± 27.58   137.26 ± 19.17   137.10 ± 20.16   140.63 ± 23.11   0.961
  DBP (mm Hg)            79.20 ± 14.04      79.69 ± 11.35          75.96 ± 10.16    79.13 ± 10.06    80.43 ± 11.34    79.33 ± 10.64    0.256
  FPG (mmol/L)           8.81 ± 3.27        8.49 ± 3.64            8.64 ± 3.72      5.63 ± 1.57      5.21 ± 1.03      5.35 ± 0.79      0.592
  HbA1c (mmol/mol)       7.95 ± 2.29        8.11 ± 1.93            7.88 ± 2.32      5.92 ± 0.68      5.95 ± 0.55      5.96 ± 0.72      0.575
  LDL (mmol/L)           2.32 ± 0.91        2.47 ± 0.97            2.26 ± 0.81      2.57 ± 1.00      2.54 ± 0.93      2.85 ± 0.86      0.916
  HDL (mmol/L)           1.22 ± 0.49        1.32 ± 0.46            1.26 ± 0.50      1.28 ± 0.43      1.10 ± 0.39      1.18 ± 0.45      0.788
  TG (mmol/L)            1.93 ± 1.60        1.56 ± 0.63            1.73 ± 0.99      1.23 ± 0.86      1.21 ± 0.62      1.48 ± 0.67      0.291
  Cholesterol (mmol/L)   4.39 ± 1.26        4.44 ± 1.08            4.31 ± 1.05      4.41 ± 1.18      4.29 ± 1.18      4.69 ± 1.11      0.843

*P* value \< 0.05, between T2DM and controls.

###### 

Clinical and biochemical characteristics among subjects according to genotypes of R230C.

                         T2DM (*n* = 164)   Controls (*n* = 165)   *P* value                                                           
  ---------------------- ------------------ ---------------------- ---------------- ---------------- ---------------- ---------------- -------
  Age (years)            62.19 ± 8.82       62.04 ± 10.03          62.30 ± 10.55    56.68 ± 10.60    52.80 ± 12.58    56.00 ± 12.00    0.363
  BMI (Kg/m²)            28.01 ± 5.33       27.66 ± 5.27           28.00 ± 4.26     28.60 ± 8.05     26.10 ± 4.53     26.14 ± 4.72     0.096
  WHR                    0.94 ± 0.05        0.98 ± 0.22            0.93 ± 0.05      1.02 ± 0.94      0.92 ± 0.06      0.91 ± 0.08      0.730
  SBP (mm Hg)            143.53 ± 25.25     140.19 ± 24.75         142.25 ± 20.98   139.28 ± 20.19   135.04 ± 18.38   140.82 ± 23.40   0.351
  DBP (mm Hg)            78.53 ± 13.96      77.87 ± 11.33          79.10 ± 8.65     79.70 ± 10.50    78.83 ± 10.46    80.67 ± 10.87    0.615
  FPG (mmol/L)           8.66 ± 3.71        8.88 ± 3.32            7.93 ± 3.49      5.42 ± 0.92      5.50 ± 1.74      5.42 ± 0.90      0.193
  HbA1c (mmol/mol)       8.10 ± 2.09        8.02 ± 2.22            7.41 ± 2.38      5.83 ± 0.67      6.01 ± 0.69      6.00 ± 0.52      0.192
  LDL (mmol/L)           2.58 ± 1.01        2.18 ± 0.78            2.13 ± 0.73      2.59 ± 0.98      2.72 ± 0.97      2.48 ± 0.87      0.241
  HDL (mmol/L)           1.33 ± 0.51        1.23 ± 0.47            1.12 ± 0.36      1.18 ± 0.41      1.23 ± 0.34      1.20 ± 0.60      0.494
  TG (mmol/L)            1.78 ± 1.08        1.70 ± 1.23            1.89 ± 1.42      1.29 ± 0.78      1.32 ± 0.83      1.14 ± 0.54      0.968
  Cholesterol (mmol/L)   4.69 ± 1.22        4.16 ± 1.07            4.08 ± 0.88      4.40 ± 1.24      4.56 ± 1.09      4.25 ± 1.17      0.119

*P* value \< 0.05, between T2DM and controls.

###### 

Conflicting results of genetic variants found in different populations.

  Gene variants               Diseases           Populations     References                                   Number of subjects   *P* value
  --------------------------- ------------------ --------------- -------------------------------------------- -------------------- -----------
  ABCA1 R1587K                CAD                Chinese         Guo et al., 2011 \[[@B14]\]                  222                  NS
  ABCA1 R219K                 CHD                Turkish         Çoban et al., 2014 \[[@B15]\]                627                  NS
  ABCA1 C69T                  CAD                Turkish         Ergen et al., 2008 \[[@B16]\]                127                  NS
  ABCA1 R219K                 CHD                Spanish         Cenarro et al., 2003 \[[@B17]\]              216                  S
  ABCA1 C69T                  T2DM               Saudi Arabian   Alharbi et al., 2013 \[[@B9]\]               756                  S
  ABCA1 C69T                  T2DM               Turkish         Ergen et al., 2012 \[[@B10]\]                157                  S
  ABCA1 R219K, R1587K, C69T   T2DM               French          Porchay-Baldérelli et al., 2009 \[[@B18]\]   482                  NS
  ABCA1 R230C                 CAD                Mexican         Villarreal-Molina et al., 2012 \[[@B13]\]    2193                 S
  ABCA1 R219K                 Overweight/obese   Thai            Kitjaroentham et al., 2007 \[[@B11]\]        229                  NS
  ABCA1 R219K, R1587K, C69T   Ischemic stroke    English         Pasdar et al., 2007 \[[@B19]\]               887                  S
  ABCA1 R1219K                CAD                American        Benton et al., 2007 \[[@B20]\]               6814                 NS
  R219K                       T2DM               Malaysian       Current study                                164                  S

NS: nonsignificant (*P* \> 0.05), S: significant (*P* \< 0.05).

[^1]: Academic Editor: Aziz Ghahary
